Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5 - Implications for dementia with Lewy bodies

Molecular Neurodegeneration

Volumn 9, Issue 1, 2014, Pages

  Overk, Cassia R ^a   Cartier, Anna ^a   Shaked, Gideon ^a   Rockenstein, Edward ^a   Ubhi, Kiren ^a   Spencer, Brian ^a   Price, Diana L ^b   Patrick, Christina ^a   Desplats, Paula ^a   Masliah, Eliezer ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Neuropore Therapies   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyloid oligomer; Dementia with Lewy body; Hippocampus; Human; mGluR5; Parkinsonism; Transgenic animal model; synuclein

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CALCIUM; CALPAIN; CASPASE 3; LENTIVIRUS VECTOR; MESSENGER RNA; METABOTROPIC RECEPTOR 5; MICROTUBULE ASSOCIATED PROTEIN 2; SHORT HAIRPIN RNA; SYNAPTOPHYSIN;

ANIMAL CELL; ARTICLE; BIOACCUMULATION; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL DEATH; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DOWN REGULATION; ENZYME ACTIVATION; GENE EXPRESSION; GENE TRANSFER; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; HIPPOCAMPAL NEURONAL CULTURE; HIPPOCAMPUS; MOUSE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PYRAMIDAL NERVE CELL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALIA; MUS; MUS MUSCULUS;

ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LEWY BODY DISEASE; MICE; MICE, TRANSGENIC; NEURONS; RATS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, METABOTROPIC GLUTAMATE 5;

EID: 84901979360     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-9-18     Document Type: Article

References (79)

1. Alzheimer's disease facts and figures. As A, Alzheimer's Dementia 2013 2013 9 1 71
2. Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease. Masters CL, Selkoe DJ, Cold Spring Harb Perspect Med 2012 2 006262 22675658
3. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Mucke L, Selkoe DJ, Cold Spring Harb Perspect Med 2012 2 006338 22762015
4. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and lewy body dementia. Trojanowski J, Goedert M, Iwatsubo T, Lee V, Cell Death Differ 1998 5 832 837 10.1038/sj.cdd.4400432 10203692 (Pubitemid 28484393)
5. Alpha-synuclein in Lewy bodies. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M, Nature 1997 388 839 840 10.1038/42166 9278044 (Pubitemid 27377048)
6. Human recombinant NACP/a-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Hashimoto M, Hernandez-Ruiz S, Hsu L, Sisk A, Xia Y, Takeda A, Sundsmo M, Masliah E, Brain Res 1998 799 301 306 10.1016/S0006-8993(98)00514-9 9675319 (Pubitemid 28351261)
7. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA, Hardy J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Leverenz JB, Masliah E, McKeith IG, Nussbaum RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, et al. Neurology 2007 68 812 819 10.1212/01.wnl.0000256715.13907.d3 17353469 (Pubitemid 46568532)
8. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. McKeith IG, J Alzheimers Dis 2006 9 417 423 16914880 (Pubitemid 44253336)
9. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, Marsh L, Troncoso JC, Neurobiol Aging 2005 26 1183 1192 10.1016/j.neurobiolaging.2004.10.006 15917102 (Pubitemid 40726011)
10. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, Nee LE, O'Connell B, Pollen DA, St George-Hyslop P, Ghetti B, Nochlin D, Bird TD, Cairns NJ, Lee VM, Iwatsubo T, Trojanowski JQ, Am J Pathol 1998 153 1365 1370 10.1016/S0002-9440(10)65722-7 9811326 (Pubitemid 28509891)
11. Cross-seeding of misfolded proteins: implications for etiology and pathogenesis of protein misfolding diseases. Morales R, Moreno-Gonzalez I, Soto C, PLoS Pathog 2013 9 1003537 10.1371/journal.ppat.1003537 24068917
12. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L, Proc Natl Acad Sci U S A 2001 98 12245 12250 10.1073/pnas.211412398 11572944 (Pubitemid 32959858)
13. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer B, Rockenstein E, Trejo M, Platoshyn O, Yuan JX, Masliah E, PLoS One 2008 3 3135 10.1371/journal.pone.0003135 18769546
14. Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R, Neurochem Res 2006 31 1153 1162 10.1007/s11064-006-9140-9 16947080 (Pubitemid 44379676)
15. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM, J Neurosci 2010 30 7281 7289 10.1523/JNEUROSCI.0490-10.2010 20505094
16. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Hamilton RL, Brain Pathol 2000 10 378 384 10885656 (Pubitemid 30431290)
17. Selective dendritic degeneration of medium spiny neurons in dementia with Lewy bodies. Zaja-Milatovic S, Keene CD, Montine KS, Leverenz JB, Tsuang D, Montine TJ, Neurology 2006 66 1591 1593 10.1212/01.wnl.0000216137.09685.c1 16717229 (Pubitemid 43958566)
18. Selective hippocampal neuron loss in dementia with Lewy bodies. Harding AJ, Lakay B, Halliday GM, Ann Neurol 2002 51 125 128 10.1002/ana.10071 11782993 (Pubitemid 34027986)
19. Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy - implications for excitotoxicity. Price DL, Rockenstein E, Ubhi K, Phung V, MacLean-Lewis N, Askay D, Cartier A, Spencer B, Patrick C, Desplats P, Ellisman MH, Masliah E, PLoS One 2010 5 14020 10.1371/journal.pone.0014020 21103359
20. Metabotropic glutamate receptors in neurodegeneration/neuroprotection: still a hot topic? Caraci F, Battaglia G, Sortino MA, Spampinato S, Molinaro G, Copani A, Nicoletti F, Bruno V, Neurochem Int 2012 61 559 565 10.1016/j.neuint.2012.01.017 22306345
21. The role of metabotropic glutamate receptors in Alzheimer's disease. Lee HG, Zhu X, O'Neill MJ, Webber K, Casadesus G, Marlatt M, Raina AK, Perry G, Smith MA, Acta Neurobiol Exp (Wars) 2004 64 89 98 15190683 (Pubitemid 38453809)
22. Glutamate receptors and Parkinson's disease: opportunities for intervention. Marino MJ, Valenti O, Conn PJ, Drugs Aging 2003 20 377 397 10.2165/00002512-200320050-00006 12696997 (Pubitemid 36520959)
23. mGluRs: a target for pharmacotherapy in Parkinson disease. Feeley Kearney JA, Albin RL, Exp Neurol 2003 184 Suppl 1 30 S36 14597323
24. Regulation by metabotropic glutamate receptor 5 of LTP in the dentate gyrus of freely moving rats: relevance for learning and memory formation. Naie K, Manahan-Vaughan D, Cereb Cortex 2004 14 189 198 10.1093/cercor/bhg118 14704216 (Pubitemid 38141534)
25. The role of metabotropic glutamate receptor 5 in learning and memory processes. Simonyi A, Schachtman TR, Christoffersen GR, Drug News Perspect 2005 18 353 361 10.1358/dnp.2005.18.6.927927 16247513 (Pubitemid 43073869)
26. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. Romano C, Sesma MA, McDonald CT, O'Malley K, Van den Pol AN, Olney JW, J Comp Neurol 1995 355 455 469 10.1002/cne.903550310 7636025
27. Localization and physiological roles of metabotropic glutamate receptors in the direct and indirect pathways of the basal ganglia. Marino MJ, Awad H, Poisik O, Wittmann M, Conn PJ, Amino Acids 2002 23 185 191 10.1007/s00726-001- 0127-1 12373536
28. Metabotropic glutamate receptors in the basal ganglia motor circuit. Conn PJ, Battaglia G, Marino MJ, Nicoletti F, Nat Rev Neurosci 2005 6 787 798 10.1038/nrn1763 16276355 (Pubitemid 41679241)
29. Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the cerebral cortex in Alzheimer's disease and dementia with Lewy bodies correlates with stage of Alzheimer's-disease-related changes. Albasanz JL, Dalfo E, Ferrer I, Martin M, Neurobiol Dis 2005 20 685 693 10.1016/j.nbd.2005.05.001 15949941 (Pubitemid 41619345)
30. beta-Amyloid peptides impair PKC-dependent functions of metabotropic glutamate receptors in prefrontal cortical neurons. Tyszkiewicz JP, Yan Z, J Neurophysiol 2005 93 3102 3111 10.1152/jn.00939.2004 15659527 (Pubitemid 40720893)
31. The up-regulation of metabotropic glutamate receptor 5 (mGluR5) in Down's syndrome brains. Oka A, Takashima S, Acta Neuropathol (Berl) 1999 97 275 278 10.1007/s004010050985 10090675 (Pubitemid 29137277)
32. Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Battaglia G, Busceti CL, Molinaro G, Biagioni F, Storto M, Fornai F, Nicoletti F, Bruno V, J Neurosci 2004 24 828 835 10.1523/JNEUROSCI.3831-03.2004 14749427 (Pubitemid 38146593)
33. Neuroprotective activity of metabotropic glutamate receptor ligands. Flor PJ, Battaglia G, Nicoletti F, Gasparini F, Bruno V, Adv Exp Med Biol 2002 513 197 223 12575822 (Pubitemid 36332408)
34. Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP. Aguirre JA, Kehr J, Yoshitake T, Liu FL, Rivera A, Fernandez-Espinola S, Andbjer B, Leo G, Medhurst AD, Agnati LF, Fuxe K, Brain Res 2005 1033 216 220 10.1016/j.brainres.2004.11.040 15694927 (Pubitemid 40193417)
35. Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. Vernon AC, Palmer S, Datla KP, Zbarsky V, Croucher MJ, Dexter DT, Eur J Neurosci 2005 22 1799 1806 10.1111/j.1460-9568.2005.04362.x 16197521 (Pubitemid 41482969)
36. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E, J Neurosci Res 2001 66 573 582 10.1002/jnr.1247 11746377 (Pubitemid 33032326)
37. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E, J Neurosci Res 2002 68 568 578 10.1002/jnr.10231 12111846 (Pubitemid 34575622)
38. MGLuR5 activation reduces beta-amyloid-induced cell death in primary neuronal cultures and attenuates translocation of cytochrome c and apoptosis-inducing factor. Movsesyan VA, Stoica BA, Faden AI, J Neurochem 2004 89 1528 1536 10.1111/j.1471-4159.2004.02451.x 15189356 (Pubitemid 38802674)
39. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R, J Neurosci 2004 24 3370 3378 10.1523/JNEUROSCI.1633-03.2004 15056716 (Pubitemid 38451902)
40. The inhibition of glycogen synthase kinase 3beta by a metabotropic glutamate receptor 5 mediated pathway confers neuroprotection to Abeta peptides. Liu F, Gong X, Zhang G, Marquis K, Reinhart P, Andree TH, J Neurochem 2005 95 1363 1372 10.1111/j.1471-4159.2005.03474.x 16277616 (Pubitemid 41779261)
41. Mechanism of membrane depolarization caused by the Alzheimer Abeta1-42 peptide. Blanchard BJ, Thomas VL, Ingram VM, Biochem Biophys Res Commun 2002 293 1197 1203 10.1016/S0006-291X(02)00346-7 12054502 (Pubitemid 34681068)
42. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A, Neuron 2010 66 739 754 10.1016/j.neuron.2010.04.029 20547131
43. Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors. Lea PM, Movsesyan VA, Faden AI, Br J Pharmacol 2005 145 527 534 15821750 (Pubitemid 40966282)
44. Different species of alpha-synuclein oligomers induce calcium influx and seeding. Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M, J Neurosci 2007 27 9220 9232 10.1523/JNEUROSCI.2617-07.2007 17715357 (Pubitemid 47312071)
45. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Arispe N, Rojas E, Pollard HB, Proc Natl Acad Sci U S A 1993 90 567 571 10.1073/pnas.90.2.567 8380642 (Pubitemid 23028904)
46. Calcium dyshomeostasis and neurotoxicity of Alzheimer's beta-amyloid protein. Kawahara M, Negishi-Kato M, Sadakane Y, Expert Rev Neurother 2009 9 681 693 10.1586/ern.09.28 19402778
47. Calpain-cleavage of {alpha}-synuclein: connecting proteolytic processing to disease-linked aggregation. Dufty BM, Warner LR, Hou ST, Jiang SX, Gomez-Isla T, Leenhouts KM, Oxford JT, Feany MB, Masliah E, Rohn TT, Am J Pathol 2007 170 1725 1738 10.2353/ajpath.2007.061232 17456777 (Pubitemid 47339316)
48. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. Mishizen-Eberz AJ, Guttmann RP, Giasson BI, Day GA 3rd, Hodara R, Ischiropoulos H, Lee VM, Trojanowski JQ, Lynch DR, J Neurochem 2003 86 836 847 10.1046/j.1471-4159.2003.01878.x 12887682 (Pubitemid 36988796)
49. Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Mishizen-Eberz AJ, Norris EH, Giasson BI, Hodara R, Ischiropoulos H, Lee VM, Trojanowski JQ, Lynch DR, Biochemistry 2005 44 7818 7829 10.1021/bi047846q 15909996 (Pubitemid 40740765)
50. Parkin cleaves intracellular alpha-synuclein inclusions via the activation of calpain. Kim SJ, Sung JY, Um JW, Hattori N, Mizuno Y, Tanaka K, Paik SR, Kim J, Chung KC, J Biol Chem 2003 278 41890 41899 10.1074/jbc. M306017200 12917442 (Pubitemid 37310450)
51. Axonopathy in an alpha-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated alpha-synuclein. Games D, Seubert P, Rockenstein E, Patrick C, Trejo M, Ubhi K, Ettle B, Ghassemiam M, Barbour R, Schenk D, Nuber S, Masliah E, Am J Pathol 2013 182 940 953 10.1016/j.ajpath.2012.11.018 23313024
52. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM, J Exp Med 2012 209 975 986 10.1084/jem.20112457 22508839
53. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120) : implications for Lewy body disorders. Tofaris GK, Garcia Reitbock P, Humby T, Lambourne SL, O'Connell M, Ghetti B, Gossage H, Emson PC, Wilkinson LS, Goedert M, Spillantini MG, J Neurosci 2006 26 3942 3950 10.1523/JNEUROSCI.4965-05.2006 16611810 (Pubitemid 44315414)
54. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M, Eur J Neurosci 2010 32 409 422 10.1111/j.1460-9568. 2010.07284.x 20704592
55. Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. Daher JP, Ying M, Banerjee R, McDonald RS, Hahn MD, Yang L, Flint Beal M, Thomas B, Dawson VL, Dawson TM, Moore DJ, Mol Neurodegener 2009 4 34 10.1186/1750-1326-4-34 19630976
56. A progressive dopaminergic phenotype associated with neurotoxic conversion of alpha-synuclein in BAC-transgenic rats. Nuber S, Harmuth F, Kohl Z, Adame A, Trejo M, Schonig K, Zimmermann F, Bauer C, Casadei N, Giel C, Calaminus C, Pichler BJ, Jensen PH, Muller CP, Amato D, Kornhuber J, Teismann P, Yamakado H, Takahashi R, Winkler J, Masliah E, Riess O, Brain 2013 136 412 432 10.1093/brain/aws358 23413261
57. Amyloid-beta and Alzheimer's disease type pathology differentially affects the calcium signalling toolkit in astrocytes from different brain regions. Grolla AA, Sim JA, Lim D, Rodriguez JJ, Genazzani AA, Verkhratsky A, Cell Death Dis 2013 4 623 10.1038/cddis.2013.145 23661001
58. Positive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders. Cleva RM, Olive MF, Molecules 2011 16 2097 2106 10.3390/molecules16032097 21368721
59. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, Vortmeyer A, Wisniewski T, Koleske AJ, Gunther EC, Nygaard HB, Strittmatter SM, Neuron 2013 79 887 902 10.1016/j.neuron.2013.06.036 24012003
60. Amyloid beta deregulates astroglial mGluR5-mediated calcium signaling via calcineurin and Nf-kB. Lim D, Iyer A, Ronco V, Grolla AA, Canonico PL, Aronica E, Genazzani AA, Glia 2013 61 1134 1145 10.1002/glia.22502 23616440
61. Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model. Hsieh MH, Ho SC, Yeh KY, Pawlak CR, Chang HM, Ho YJ, Lai TJ, Wu FY, Pharmacol Biochem Behav 2012 102 64 71 10.1016/j.pbb.2012.03.022 22487770
62. Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease. Black YD, Xiao D, Pellegrino D, Kachroo A, Brownell AL, Schwarzschild MA, Neurosci Lett 2010 486 161 165 10.1016/j.neulet.2010.09.043 20854878
63. Examining the mechanisms that link beta-amyloid and alpha-synuclein pathologies. Marsh SE, Blurton-Jones M, Alzheimers Res Ther 2012 4 11 10.1186/alzrt109 22546279
64. alpha-synuclein induced synapse damage is enhanced by amyloid-beta1-42. Bate C, Gentleman S, Williams A, Mol Neurodegener 2010 5 55 10.1186/1750-1326-5- 55 21138585
65. Cross-seeding effects of amyloid beta-protein and alpha-synuclein. Ono K, Takahashi R, Ikeda T, Yamada M, J Neurochem 2012 122 883 890 10.1111/j.1471-4159.2012.07847.x 22734715
66. α-Synuclein/Amyloid Interactions. Henning Jensen P, Methods Mol Med 2001 62 61 65 21318767
67. Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. Bar-On P, Crews L, Koob AO, Mizuno H, Adame A, Spencer B, Masliah E, J Neurochem 2008 105 1656 1667 10.1111/j.1471-4159.2008.05254.x 18248604 (Pubitemid 351678486)
68. Design and cloning of lentiviral vectors expressing small interfering RNAs. Tiscornia G, Singer O, Verma IM, Nat Protoc 2006 1 234 240 10.1038/nprot.2006.36 17406238
69. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, Adame A, Wyss-Coray T, Masliah E, J Neurosci 2009 29 13578 13588 10.1523/JNEUROSCI.4390-09.2009 19864570
70. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH, Verma IM, Masliah E, J Neurosci 2003 23 1992 1996 12657655 (Pubitemid 36368884)
71. Franklin KBJ, Paxinos G, The mouse brain in stereotaxic coordinates San Diego: Academic Press 1997
72. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, Lee J, Truong J, Andrews-Zwilling Y, Hsieh EW, Louie JY, Wu T, Scearce-Levie K, Patrick C, Adame A, Giorgini F, Moussaoui S, Laue G, Rassoulpour A, Flik G, Huang Y, Muchowski JM, Masliah E, Schwarcz R, Muchowski PJ, Cell 2011 145 863 874 10.1016/j.cell.2011.05.020 21640374
73. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L, Science 2000 287 1265 1269 10.1126/science.287.5456.1265 10678833 (Pubitemid 30112148)
74. Brainstem Alzheimer's-like pathology in the triple transgenic mouse model of Alzheimer's disease. Overk CR, Kelley CM, Mufson EJ, Neurobiol Dis 2009 35 415 425 10.1016/j.nbd.2009.06.004 19524671
75. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L, Buttini M, Games D, Schenk D, PLoS One 2011 6 19338 10.1371/journal.pone.0019338 21559417
76. Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A, Salmon D, Galasko D, Michael S, Savas JN, Yates JR, Glabe C, Masliah E, FEBS J 2010 277 3051 3067 20573181
77. b-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E, Neuron 2001 32 213 223 10.1016/S0896-6273(01)00462-7 11683992 (Pubitemid 33030190)
78. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ, Nature 2002 416 535 539 10.1038/416535a 11932745 (Pubitemid 34288854)
79. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE, J Clin Invest 2006 116 193 201 16341263 (Pubitemid 43121804)